Evidence map›Paper›PMID 41362743›Full record

ArticleInternational journal of biological sciences2026

Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/β-Catenin pathway.

Lijing Zhong, Dongyan Cao, Chen Zheng, Liyi Zhang, Yuxuan Xu, Shasha Zhao, Xiao Liu, Guiying Wei, Gengming Niu, Heming Xu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lijing ZhongState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Dongyan CaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Chen ZhengState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Liyi ZhangDepartment of Breast Surgery, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Yuxuan XuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Shasha ZhaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Xiao LiuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Guiying WeiShanghai OneTar Biomedicine, Shanghai, People's Republic of China.
Gengming NiuShanghai OneTar Biomedicine, Shanghai, People's Republic of China.
Heming XuShanghai OneTar Biomedicine, Shanghai, People's Republic of China.
Xuan TangDepartment of Oncology, the Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
Jingyuan WenSchool of Pharmacy, Faculty of Medical and Health Sciences, and Maurice Wilkins Centre for Molecular Biodiversity. The University of Auckland, Auckland, New Zealand.
Paul W R HarrisSchool of Biological Sciences, School of Chemical Sciences and Maurice Wilkins Centre for Molecular Biodiversity. The University of Auckland, Auckland, New Zealand.
Jian ZhangDepartment of Phase I Clinical Trial Center, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Aina HeDepartment of Oncology, the Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
Dongxi XiangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance remains a major obstacle to successful chemotherapy, leading to treatment failure and tumor recurrence. Recent studies indicate that mutations in FAT Atypical Cadherin 1 (

Indexed as

Breast NeoplasmsCadherinsCyclophosphamideDrug Resistance, NeoplasmWnt Signaling PathwayAnimalsbeta CateninCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMicebeta CateninCadherinsCyclophosphamideFAT1 protein, humanbreast cancerdrug screening testFAT1precision medicinetumor organoids

Identifiers

PMID41362743
PMCPMC12681942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.